Nitin Jain
M.D. Anderson Cancer Center
8
8
2
N/A
0
4
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+16 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (8)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Elias Jabbour
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Elias Jabbour, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Farhad Ravandi-Kashani, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
David Avigan, MD
Beth Israel Deaconess Medical Center
Shared therapeutic areas:
Worked with same sponsors:
Agostino Tafuri
AOU Sant'Andrea
Shared therapeutic areas:
Laura Nocilli
Ospedale Papardo
Shared therapeutic areas:
Vincenzo Fraticelli
Responsible Research Hospital
Shared therapeutic areas:
Roberta Murru
Ospedale Oncologico" A. Businco" - ARNAS "G. Brotzu"
Shared therapeutic areas:
Jae Park, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Luca Laurenti
Policlinico Universitario Gemelli IRCCS
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (8)
Showing 8 of 8 trials
ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome
Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation
Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia
All 8 trials loaded